CD8A and neoplasm: As a result, OVA-liposome-KALA vaccination induced higher in vivo CD8 T-cell responses, as revealed by an in vivo cytotoxic assay, and stronger anti-tumor effect in a prophylactic vaccination protocol using EG7 tumor challenge.